Denali Therapeutics officer Peter Scott Chin proposed selling 1,654 common shares after restricted stock lapsed, with the shares sold to cover a tax obligation from vested Equity compensation. For investors, the stated purpose links the transaction to tax settlement rather than a discretionary sale, while director Nancy Thornberry separately sold 11,439 shares at $22.85-$23.74.
Key Highlights
- Director Nancy Thornberry sold 11,439 Denali Therapeutics shares in two transactions priced at $22.85-$23.74 each.
- The proposed sale followed a restricted stock lapse dated 09/03/2026.
- Morgan Stanley Smith Barney LLC is listed as the executive financial services firm connected with Peter Scott Chin’s transaction.
Denali Therapeutics Inc. (NASDAQ: DNLI) proposed the sale of 1,654 common shares by officer Peter Scott Chin after a restricted stock lapse. The transaction is tied to equity compensation and is intended to cover a tax obligation from vested Restricted Stock Units.
1,654 Shares Linked to Equity Compensation
The transaction was dated 09/03/2026 and associated with Denali Therapeutics common stock. The Form 144 information was dated 09/04/2026, and Morgan Stanley Smith Barney LLC was listed in connection with executive financial services. The related records name Peter Scott Chin as an officer of Denali Therapeutics. Director Nancy Thornberry separately sold 11,439 shares at prices ranging from $22.85 to $23.74 per share across two transactions. That transaction was identified in the source as a Form 4 sale. The records list Denali Therapeutics at 161 Oyster Point Blvd. South San Francisco, California 94,080. Peter Scott Chin’s transaction was signed on 09/04/2026 by Tyler Nielsen under power of attorney.
FAQs
Q: How many Denali Therapeutics shares did Peter Scott Chin propose selling?
A: Peter Scott Chin proposed selling 1,654 Denali Therapeutics common shares. The transaction followed a restricted stock lapse and was linked to equity compensation.
Q: Why were the Denali Therapeutics shares sold?
A: The shares were sold to cover a tax obligation from the settlement of vested Restricted Stock Units. The stated purpose was tied to equity compensation.
Q: What did Nancy Thornberry sell in Denali Therapeutics?
A: Director Nancy Thornberry sold 11,439 Denali Therapeutics shares across two transactions. The reported sale prices ranged from $22.85 to $23.74 per share.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.